Role of health-related quality of life measures in the routine care of people with multiple sclerosis
Alessandra Solari*

Address: Epidemiology Unit, National Neurological Institute C. Besta, Via Celoria 11, 20133 Milan, Italy
Email: Alessandra Solari* - solari@istituto-besta.it
* Corresponding author

Abstract
Health-related quality of life instruments are expected to be of particular value in routine care of people with multiple sclerosis (MS), where they may facilitate the detection of disease aspects that would otherwise go unrecognised, help clinicians appreciate patient priorities particularly in terms of treatment goals, facilitate physician-patient communication, and promote shared decision-making. However, it appears that these instruments are little used routine clinical approaches to people with MS. To address this issue, I performed a bibliographic search of studies that evaluated the efficacy of generic or disease-specific health-related quality of life (HRQOL) instruments in MS clinical practice from clinicians’ or patients’ perspectives. I found only one cross-sectional study, which compared preferences for three instruments, and assessed acceptability in people with MS.

Reasons for lack of transfer of HRQOL measurements to clinical practice may be cultural, methodological, or practical. With regard to MS, the proliferation of instruments seems to constitute a barrier, with no particular instrument having gained wide popularity or consensus. Other barriers are lack of resources for the administration, collection and storage of the data, and inability of clinicians to score, interpret, and use HRQOL instrument to guide clinical care. It is therefore important to refine existing tools, extending clinical validation to wider contexts and cultures. More studies assessing acceptability and clinicians’ and patients’ preferences for different instruments are also required.

Review
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system of unknown etiology and poorly understood pathogenesis. There is a north-south gradient of MS prevalence in the northern hemisphere, with highest levels (over 100 per 100,000) in northern regions [1,2]. It is a chronic disease with a modest effect on life expectancy, but a broad spectrum of consequences, of variable severity, on physical and psychological characteristics, that vary between individuals and within individuals over time. The disease typically strikes women (2:1) in their peak years of career development and family life; commonly there are exacerbations and remissions followed by progression whose rate and extent vary [3]. There is also a benign form of MS, characterised by few relapses, long periods of remission, and mild activity limitations over the long term [4]. The available treatments...
have at best a modest benefit on the course of the disease [5].

**Health-related quality of life measures**

Interest in measuring outcomes in MS has increased markedly over the past 20 years. Standardised instruments have been developed, the most-used being the Expanded Disability Status Scale (EDSS) [6] which is a mixed impairment/activity limitations scale based on neurological examination of eight functional systems, plus ambulation/mobility status. Despite major limitations – bias towards locomotor function, variable sensitivity to change according to scale score, and suboptimal inter-rater reliability – the EDSS is widely-used by researchers and clinicians because its scores are readily understood by all.

More recently, the importance of MS outcome assessment from the perspective of the person with the disease has been recognised [7]. After 1992, the number of publications on health-related quality of life (HRQOL) increased steadily, as did those employing MS-specific instruments (see Figure). Generic instruments were applied to MS [7-12], and disease-specific instruments were devised and validated [13-24]. The seven available MS-specific HRQOL instruments are listed in the Table 1; all were published between 1995 and 2001. Three consist of a generic module (SF-36 [13,15] or FACT-G [14]) plus an MS-specific module. In most cases people with MS participated in their development [13,16]. Except for the MS Quality of Life 54 (MSQOL-54), which has been translated into several languages [13,20-23], and the Functional Assessment of MS (FAMS), which is also available in Portuguese [24], these questionnaires are available only in their original versions. Aspects of responsiveness were evaluated in four of the seven instruments, but in general sensitivity to change has been insufficiently investigated [18,25-28].

### Table 1: Characteristics of MS-specific HRQOL questionnaires

| Questionnaire   | Publication year | Generic module | MS module | People with MS involved in development | Versions                          | Reliability | Responsiveness | Domains not assessed | Time period assessed | Time to complete | Publications (no.) | Publication period |
|-----------------|------------------|----------------|-----------|----------------------------------------|----------------------------------|-------------|-----------------|----------------------|--------------------|------------------|-------------------|-------------------|
| MSQOL-54        | 1995             | SF-36 (36 items) | 18 items  | No                                     | US English [13]                  | Alpha        | RCT             | Vision               | Past 4 weeks        | 20 minutes       | 16                | 1995–2004         |
| FAMS            | 1996             | FACT-G (28 items) | 31 items  | Yes                                    | Italian [20]                     | Alpha        | RCT             | Bladder/ bowel       | Current time        | 20 minutes       | 10                | 1996–2004         |
| MSQOLI          | 1999             | SF-36 (36 items) | 9 scales  | Yes                                    | US English [14]                  | Alpha        | Test-retest     | Vision               | Past week           | --               | 5                 | 1999–2003         |
| RAYS            | 2000             | --              | 50 items  | No                                     | --                               | Alpha        | Test-retest     | Bladder/ bowel       | Past week           | --               | 1                 | 2000              |
| HAQUAMS         | 2001             | --              | 38 items  | Yes                                    | Hebrew [16]                      | Alpha        | Test-retest     | Vision               | Past year           | --               | M                  | 2001–2004         |
| MSIS-29         | 2001             | --              | 29 items  | Yes                                    | German [17]                      | Alpha        | Test-retest     | Vision               | Past 2 weeks        | --               | Yes               | 2001–2004         |
| LMSQoL          | 2001             | --              | 8 items   | Yes                                    | English [18]                      | Alpha        | Test-retest     | Vision               | Past month          | --               | Yes               | 2001              |

MSQOL-54 is the MS quality-of-life 54; FAMS is the Functional Assessment of MS; MSQOLI is the MS Quality of Life; HAQUAMS is the Hamburg Quality of Life Questionnaire in MS; FACT-G is the Functional Assessment of Cancer Therapy, General version; LMSQoL is the Leeds MS Quality of Life. Alpha is Cronbach’s coefficient alpha. RCT aspects of responsiveness assessed in randomized controlled trial.
in routine care, where they may improve the detection of disease aspects that would otherwise go unrecognised, help clinicians appreciate patient priorities particularly in terms of treatment goals, facilitate physician-patient communication, and promote shared decision making. In addition HRQOL data from clinical trials can provide information that clinicians can usefully discuss with their patients [36]. Unfortunately, although recent MS trials include some HRQOL assessment, there is no internationally agreed gold standard for conducting such assessment or reporting outcomes. HRQOL evaluations are not required as endpoints in MS trials by the European Agency for the Evaluation of Medicinal Products [37]. Even when HRQOL endpoints are included, data collection and reporting are often of poor quality [38] with the consequence that cost effectiveness issues, which HRQOL instruments can throw light on, such as preserved function, less work missed, and improved emotional well-being, are not analysed.

**Literature survey**

It appears that HRQOL instruments are little used in routine clinical approaches to people with MS. To address this issue, I searched MEDLINE (1966–2004), the Cochrane Library (Issue 1, 2005) and the Cochrane MS Group trials register (2004) for studies that evaluated the efficacy of generic or MS-specific HRQOL instruments in clinical practice from the clinicians’ or MS patients’ perspective, also checking study references. Studies considering patient-reported outcomes other than HRQOL, and domain-specific measures were excluded.

I found only one study, a cross-sectional postal survey conducted in Canada, published in 2004 [39]. This study assessed MS sufferers’ preferences regarding two generic instruments (the EuroQol EQ-5D and the SF-36), and an MS-specific instrument (MSQOL-54). Over 90% of 183 participants reported that EuroQol EQ-5D and the SF-36 were acceptable or very acceptable, and 85% did so for MSQOL-54. Surprisingly, over 75% of participants felt that a combination of the three instruments best described their HRQOL.

The reasons for lack of transfer of HRQOL assessment into clinical practice may be cultural, practical, or methodological [40-43]. With regard to cultural factors, patients generally welcome the opportunity to provide clinicians with information regarding their HRQOL [43]. That this is also the case for people with MS is suggested by high participation rates in most postal surveys assessing patient-reported health status [30,35,39,44], and by the good acceptability of HRQOL instruments [39]. By contrast, information on practicing clinicians’ perceptions of the utility of HRQOL data is limited and conflicting: studies have uncovered a lack of knowledge of HRQOL as well as concerns that these instruments may be a covert means of assessing physicians’ performance [45,46].

Practical considerations be particularly important in clinical settings, where data must be provided promptly and in an understandable manner to be of use. Instruments must be administered, processed, scored, stored and retrieved – all of which have logistic and financial implications [47]. Most HRQOL instruments are lengthy and may be burdensome for patients and clinicians. For most existing instruments, the score is not immediately available, but needs to be calculated, while score interpretation may not be straightforward. For example a recently published study on transplant physicians found that 55% would be more likely to use HRQOL data if it were more comprehensible [48]. In the United States time spent gathering and interpreting HRQOL information as part of the clinical encounter is not built into reimbursement by third-party payers [49]. It is noteworthy, however, that questionnaire length seems not to be a drawback for people with MS since a combination of HRQOL instruments was preferred by over 75% of participants in the only study found [39].

Another factor limiting the dissemination of HRQOL tools in MS clinical practice is likely to be that too many instruments are available, and unlike EDSS, none has emerged as clearly superior to any other.
Acknowledgements

I am indebted to Dr. Barbara Vickrey and Dr. Christoph Heesen for their helpful suggestions for improving the manuscript. Thanks are also due to Dr. Maura Moggia, trial search coordinator of the Cochrane MS Group, for providing the search strategy, and to Mrs. Giusi Ferrari for retrieving the historical paper-and-pencil or interview methods, which should of course be evaluated for acceptability and reliability [48]. The objective is not to add HRQOL measurements to the chores of everyday practice, but to incorporate meaningful HRQOL instruments into the care process [50].

References

1. Compton A: Genetic epidemiology of multiple sclerosis. J Neurol Neurosurg Psychiatry 1997, 62:553-561.
2. Kurtzke JF: Geography in multiple sclerosis. J Neurol 1977, 215:1-26.
3. Sadovnick AD, Ebers GC: Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 1993, 20:17-29.
4. Pitcock SJ, McClelland RL, Mayr WT, Jorgensen NW, Weishenker BG, Noseworthy J, Rodriguez M: Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Ann Neurol 2004, 56:303-306.
5. Filippini G, Munari L, Incorvaia B: Interferons in relapsing-remitting multiple sclerosis: a systematic review. Lancet 2003, 362:545-552.
6. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. Neurology 1983, 33:1441-1442.
7. Rothwell PM, McDowell Z, Wong CK, Dorman PJ: Doctors and patients don't agree: cross sectional study of patients and doctors perceptions and assessments of disability in multiple sclerosis. BMJ 1997, 314:1580-1583.
8. Aronson KJ: Quality of life among persons with multiple sclerosis and their caregivers. Neurology 1997, 48:74-80.
9. Brunet DG, Hopman WM, Singer MA, Edgar CM, MacKenzie TA: Measurement of health-related quality of life in multiple sclerosis patients. Can J Neurol Sci 1996, 23:99-103.
10. Burden of illness of multiple sclerosis: Part II: Quality of life. The Canadian Burden of Illness Study Group. Can J Neurol Sci 1998, 25:31-38.
11. Pfennings LEMA, Cohen L, Van der Ploeg HM: Assessing the quality of life in patients with multiple sclerosis. In Multiple sclerosis: clinical changes and controversies Edited by: Thompson AJ, Polman C, Hofhaidl R. London: Martin Dunitz; 1997.
12. Lintern TC, Beaumont G, Kenealy PM, Murrell RC: Quality of life (QoL) in severely disabled multiple sclerosis patients: Comparison of three QoL measures using multidimensional scaling. Qual Life Res 2001, 10:371-378.
13. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW: A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995, 4:187-206.
14. Cella DF, Dineen MA, Arason B, Reder A, Webster KA, karabassis G, Chang C, Lloyd S, Steward J, Stedeford D: Validation of the Functional Assessment of Multiple Sclerosis Quality of Life instrument. Neurology 1996, 47:129-139.
15. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D: Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999, 5:191-199.
16. Rostein Z, Barak T, Noy S, Achorian A: Quality of life in multiple sclerosis: development and validation of the "RAYS" scale and comparison with the SF-36. Int J Qual Health Care 2000, 12:511-517.
17. Gold SM, Heesen C, Schulz H, Guder U, Monch A, Gbadamosi J, Buhmann C, Schulz KH: Disease-specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in multiple sclerosis (HAQUAMS). Mult Scler 2001, 7:119-130.
18. Hobart JC, Lamping DL, Fitzpatrick R, Riazi A, Thompson A: The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001, 124:962-973.
19. Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH: Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil 2001, 15:247-258.
20. Solari A, Filippini G, Mendoza L, Grezzi A, Cifani S, Barbieri E, Baldini S, Salmeggi A, LaMantia L, Farinotti M, Caputo D, Mosconi P: Validation of Italian multiple sclerosis quality of life 54 questionnaire. J Neurol Neurosurg Psychiatry 1999, 67:158-162.
21. Verhey D, Gerbaud J, Biolley J, Coste J, Deloire D, Beneton C, Colamarino R, Glander PY, Dordain G, Clavelou P: Quality of life and multiple sclerosis: validation of the French version of the self-questionnaire (SEP-59). Rev Neurol 2000, 156:247-263.
22. Acquadro C, Lafortune L, Mear I: Quality of life in multiple sclerosis: translation in French Canadian of the MSQoL-54. Health Qual Life Outcomes 2003, 1:70.
23. Yamamoto T, Ogata K, Katagishi M, Shimizu H, Ogawa M, Yamamura T, Kawai M: Validation of the Japanese-translated version Multiple Sclerosis Quality of Life-54 instrument. Rinsho Shinkigaku 2004, 44:417-421.
24. Mendes MF, Balsimelli S, Stangehaus G, Tilbery CP: Validation of the functional assessment of multiple sclerosis quality of life instrument in a Portuguese language. Arq Neuropsiquiatr 2004, 62:108-113.
25. Lincoln NB, Dent A, Harding J, Weyman N, Nicholl C, Blumhardt LD, Playford ED: Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002, 72:93-98.
26. Solari A, Motza A, Mendoza L, Pucci E, Forni M, Mancardi G, Pozzilli C: Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial. J Neurol Sci 2004, 222:99-104.
27. Cohen JA, Curter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN: Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 2002, 59:679-687.
28. Schulz KH, Gold SM, Witte J, Bartsch K, Lang UE, Heilweg R, Reer R, Braunmann KM, Heesen C: Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J Neurol Sci 2004, 225:1-18.
29. Lobenzani IS, Aserinbaum S, Vass K, Sauter C, Klossch G, Kollegger H, Kristoffertsch W, Zeihofer J: Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 2004, 110:6-13.
30. Solari A, Radice D: Health status of people with multiple sclerosis: a community mail survey. Neurol Sci 2001, 22:307-315.
31. Henriksson F, Fredriksson S, Masterman T, Jonsson : Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001, 8:27-35.
32. Amato MP, Porziani G, Rossi E, Liedl CL, Stefanelle C, Rossi L: Quality of life in multiple sclerosis: the impact of depression, fatigue, and disability. Mult Scler 2001, 7:340-344.
33. Wang J, Reimer MA, Metz LM, Patten SB: Major depression and quality of life in individuals with multiple sclerosis. Int J Psychiatry Med 2000, 30:209-217.
34. Grenning M, Hannisdal E, Mellgren SI: Multivariate analyses of factors associated with unemployment in people with multiple sclerosis. J Neurol Neurosurg Psychiatry 1990, 53:388-390.
35. Ford HL, Gerry E, Johnson MH, Tennant A: Health status and quality of life measure of people with multiple sclerosis. *Disabil Rehabil* 2001, 23:516-521.
36. Vickrey BG: Getting oriented to patient-oriented outcomes. *Neurology* 1999, 53:662-663.
37. Note for guidance on clinical investigation of medicinal products for the treatment of multiple sclerosis [http://www.emea.eu.int/pdfs/human/ewp/056198en.pdf], last accessed March 2005.
38. Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet* 2001, 357:1191-1194.
39. Moore F, Wolfson C, Alexandrov L, Lapierre Y: Do general and multiple sclerosis-specific quality of life instruments differ? *Can J Neurol Sci* 2004, 31:64-71.
40. Deyo RA, Patrick DL: Barriers to the use of health status measures in clinical investigation, patient care, and policy research. *Med Care* 1989, 27:S252-S268.
41. Mchorney CA, Taylor AR: Individual-patient monitoring in clinical practice: are available health status surveys adequate? *Qual Life Res* 1995, 4:293-307.
42. Rubenstein LV, McCoy JM, Cope DW, Barrett PA, Hirsch SH, Messer KS, Young RT: Improving patient quality of life with feedback to physicians about functional status. *J Gen Intern Med* 1995, 10:607-614.
43. Nelson EC, Landgraf JM, Hays RD, Wasson JH, Kirk JW: The functional status of patients: how can it be measured in physician’s offices? *Med Care* 1990, 28:1111-1126.
44. Somerset M, Campbell R, Sharp D, Peters T: What do people with MS want and expect from health-care services? *Health Expectations* 2001, 4:29-37.
45. Kazis LE, Callahan LF, Meenan RF, Pincus TSO: Health status reports in the care of patients with rheumatoid arthritis. *J Clin Epidemiol* 1990, 43:1243-1253.
46. Wagner AK, Ehrenberg BL, Tran TA, Bungay KM, Cynn D, Rogers WH: Patient-based health status measurement in clinical practice: a study of its impact on epilepsy patients' care. *Qual Life Res* 1997, 6:329-341.
47. Gilbody SM, House AO, Sheldon TA: Psychiatrists in the UK do not use outcomes measures. *National survey*. *Br J Psychiatry* 2002, 180:101-103.
48. Lee SJ, Joffe S, Kim HT, Socie G, Gilman AL, Wingard JR, Horowitz MM, Cella D, Syrjala KL: Physicians’ attitudes about quality of life issues in haematopoietic stem cell transplantation. *Blood* 2004, 104:2194-2200.
49. Donaldson MS: Tackling stock of health-related quality-of-life measurement in oncology practice in the United States. *J Natl Cancer Inst Monogr* 2004, 33:155-167.
50. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalder D, Cox D: Quality of life measures in health care. I: Applications and issues in assessment. *BMJ* 1992, 305:1074-1077.